Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 208

The DOI matches its Crossref record.

Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

Kantarjian, Hagop M., Talpaz, Moshe, O'Brien, Susan, Jones, Daniel, Giles, Francis, Garcia-Manero, Guillermo, Faderl, Stefan, Ravandi, Farhad, Rios, Mary Beth, Shan, Jianqin, Cortes, Jorge · 2006 · Blood

Abstract

A survival benefit for imatinib mesylate versus interferon-α therapy could not be demonstrated in the randomized study in newly diagnosed Philadelphia chromosome (Ph)–positive chronic-phase chronic myelogenous leukemia (CML) due to the high rate of crossover (90%) from interferon-α to imatinib mesylate within a year of study entry. We compared survival in 279 patients with newly diagnosed CML treated with imatinib mesylate at our institution (2000-2004) to 650 patients treated with interferon-α (1982-1997). The complete cytogenetic response rates were 87% with imatinib mesylate and 28% with interferon-α (P < .001). The estimated 3-year survival rates were 96% with imatinib mesylate and 81% with interferon-α (P < .01). Survival rates with imatinib mesylate were significantly better than with interferon-α within each of the CML prognostic risks groups. By multivariate analysis, imatinib mesylate therapy was identified as an independent favorable prognostic factor, after accounting for the impact of pretreatment factors (hazard ratio, 0.44; P < .01). By landmark analysis at 12 months, survival within each cytogenetic response category was similar with imatinib mesylate or interferon-α, suggesting that the survival benefit of imatinib mesylate (versus interferon-α in newly diagnosed CML) is through improving cytogenetic response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2006-02-004325

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 208

Metadata

Authors
Kantarjian, H. M., Talpaz, M., O'Brien, S., Jones, D., Giles, F., Garcia-Manero, G., Faderl, S., Ravandi, F., Rios, M. B., Shan, J., & Cortes, J.
Venue
Blood
Published
2006-09-15
Volume
108
Issue
6
Pages
1835-1840
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2157436488
Cited by
208
References
0
FWCI
15.13
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. https://app.cochat.ai/papers/10.1182/blood-2006-02-004325
The paper
Kantarjian, H. M., Talpaz, M., O'Brien, S., Jones, D., Giles, F., Garcia-Manero, G., Faderl, S., Ravandi, F., Rios, M. B., Shan, J., & Cortes, J. (2006). Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. https://doi.org/10.1182/blood-2006-02-004325

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.